A Study on Factors Associated with Clomifene Resistance in Infertile Women with WHO Group II Anovulation at a Teaching Hospital in Sri Lanka

Palihawadana TS¹, Dissanayake DMAB¹, Wijesinghe PS¹, Seneviratne HR²

Abstract

Background: Anovulation is a common cause of infertility and induction of ovulation with oral agents such as clomifene is the treatment of choice in women with normogonadotropic anovulation. While such treatment is able to achieve ovulation in many, some women fail to respond thus termed as having clomifene resistance. Knowledge on factors associated with such resistance would enable us to counsel patients more accurately and offer alternative treatment modalities without undue delays. This study was aimed at identifying factors associated with clomifene resistance among infertile women with WHO group II anovulation at a teaching hospital in Sri Lanka.

Method: A case control study was done at the Infertility clinic of the North Colombo teaching hospital, Ragama conducted by the department of obstetrics & Gynaecology of the University of Kelaniya. Women with WHO group II anovulation (n=128) were included and underwent induction of ovulation with clomifene citrate starting at a dose of 50mg per day, increased up to 150mg till ovulation was achieved. Those who fail to respond to a maximum dose of 150mg were termed as clomifene resistant. The factors known to be associated with clomifene resistance were compared between the two groups who responded and those who failed to respond. The study was registered with the Sri Lankan clinical trial registry maintained by the Sri Lanka Medical association. The study was funded by the National Science foundation of Sri Lanka through a research grant (Grant No: RG/2007/HS/08).

Results: Ovulation was achieved in 77.3% (n=99) of subjects and therefore the prevalence of clomifene resistance was 22.8% (n=29). Among those who responded, 41 did so at a dose of 50mg per day while 40% did with 100mg, thus over 80% achieving ovulation at a dose of 100mg per day or less. The factors associated with clomifene resistance in this population included infertility of more than three years (OR 2.06, 95%CI 1.51-9.14), presence of hirsutism (OR 2.76, 95%CI 1.18-6.46), a higher AFC (16 vs 13, p=0.04), PCOS (OR 2.99, 95%CI 1.06-8.41) and an LH:FSH ratio of > 1 (OR3.11, 95%CI 1.33-7.24). Other factors that have been described to be associated with clomifene resistance such as advanced age, a BMI > 25, and a higher ovarian volume did not show any significant associations in this study.

Discussion: This study was able to identify factors associated with clomifene resistance in a local population. Most factors identified included clinical and laboratory findings of PCOS thus highlighting the limitations in treatment success of clomifene among women with PCOS. This information may be used in clinical practice to counsel patients prior to treatment or to consider other alternative treatment options such as Letrozole or gonadotropins.

INTRODUCTION

Anovulation is the commonest cause of female infertility¹ and is seen in approximately 20-30% of couples²,³.

¹ Faculty of Medicine, University of Kelaniya
² Faculty of Medicine, University of Colombo

Correspondence: Dr. T.S. Palihawadana
E-mail: thilipali@kln.ac.lk
Competing interests: None

The WHO classification defines WHO group II anovulation as anovulation in the presence of normal levels of gonadotropins. Polycystic ovary syndrome (PCOS) makes up nearly 70% in this group⁴. The mainstay in treatment of infertility in this group is induction of ovulation. Clomifene citrate is the most commonly used oral ovulation induction agent worldwide. It is an anti-oestrogen, which blocks the oestrogen receptors at the level of the hypothalamus thus inducing FSH secretion from the anterior pituitary by interfering with the negative feedback of oestrogen. It is often used as the first line agent and other methods such as gonadotropins are reserved for patients who do not respond to clomifene citrate or fail to conceive with such treatment.

While it is an effective therapeutic agent in achieving ovulation in approx. 60-85% of cycles, pregnancy rates are much lower at 30-40%⁵,⁶. The discrepancy is thought to be due to the unwanted anti-oestrogenic effects of the medication on the developing endometrium and the cervical mucus. Therefore, clomifene citrate should be used at the minimum dose required to achieve ovulation. It is started at a dose of 50mg per day for five days at the beginning of the menstrual cycle and the dose is increased every month based on the response till ovulation achieved. If ovulation is not achieved at a maximum dose of 150mg per day, it is considered as clomifene resistance⁶.

Prediction of treatment response would enable us to identify patients who require other methods of induction of ovulation such as gonadotropins or laparoscopic ovarian drilling, in women with PCOS. This will allow the clinicians to be more informed when counselling patients about prognosis, avoid delays in achieving ovulation, and reduce overall treatment costs.

This study was aimed at assessing the incidence and identifying the factors associated with clomifene resistance among a group of infertile women with WHO group II anovulation at a teaching hospital in Sri Lanka.

METHOD

The study was carried out at the University infertility clinic of the North Colombo Teaching hospital, Ragama, Sri Lanka, conducted by...
the department of Obstetrics and Gynaecology, University of Kelaniya. A case control study design was used and included women who were diagnosed to have anovulation with normal levels of early follicular phase FSH (2-20IU/L), thus belonging to WHO group II anovulation. Women were between 18-40 years with normal levels of TSH and prolactin levels and those with any previous ovarian surgery were excluded.

All women included in the study were seen on the 2nd day of a spontaneous menstrual cycle and the FSH and LH levels in the index cycle were done. They underwent an ultrasound scan for ovarian morphology and determination of antral follicle count (AFC). Clomifene citrate was commenced at a dose of 50 mg per day for 5 days starting from the 2nd day of the menstrual cycle. Ultrasound follicle tracking was commenced from the 9th day of the cycle and continued till detection of ovulation. Absence of any dominant follicle (>10mm diameter) by the 12th day or follicle development arrest (no increase in diameter after 3 day) was taken as anovulatory. Those who fail to ovulate with such treatment had the drug dose increased by 50mg per day, in the subsequent cycles till a maximum dose of 150mg was achieved. Failure to respond to such a maximum dose was termed as clomifene resistance.

The main outcome variables compared between the two groups included age, BMI, presence of significant hirsutism, the ovarian volume, the AFC, FSH level and an abnormal FSH:LH ratio (a ratio of >1). Hirsutism was assessed using the modified Ferriman-Gallwey scoring system with a cut off score of eight. AFC was assessed by counting all ultrasound scan investigations using a GE LOGIQ 3 (GE healthcare, USA) scanner with a transvaginal transducer of 4.0-8.0 MHz.

The sample size calculation was done using previous data from a study by Imani et al, which achieved ovulation with clomifene in 77% of subjects included11. With an acceptable difference up to 10% of the assumed incidence, a sample size of 107 was calculated using WinPepi computer software, to describe the incidence of a satisfactory response to clomifene in this population. With an estimated drop up rate up to 20% a total of 128 was included in the study.

Approval for the study was obtained from the ethics review committee of the Faculty of Medicine, University of Kelaniya prior to study commencement. The trial was registered as a clinical trial with the Clinical trials registry of Sri Lanka Medical Association, a WHO affiliated registry (SLCTR/ 2008/015).

RESULTS

The total study population included 128 women with WHO group II anovulation with a mean age of 28.3 years (95%CI 27.5-29.1) and a mean BMI of 25.4 kg/m² (95% CI 24.3-26.4). Polycystic ovarian syndrome was present in 85 (66.4%) subjects.

Induction of ovulation was successful in 99 (77.3%) of subjects. They included 41 (32%) who ovulated at a dose of 50mg per day, 40 (31%) at 100mg and 18 (14%) with a dose of 150mg. Incidence of Clomifene resistance was 23% in this study group.

A comparison of predictive factors for clomifene citrate between the subjects who responded and were resistant is shown in table1.

DISCUSSION

Induction of ovulation is a common procedure undertaken in management of infertility and is offered to many patients either alone or in combination of intrauterine insemination. Clomifene citrate remains to be the most commonly used agent worldwide. Though previous studies have been done on predictive factors of treatment success in use of clomifene among WHO group II anovulation, not many studies have been done in local populations.

The study population included in this study had a PCOS prevalence of 66%, and is similar to prevalence described in other studies4. Ovulation was achieved with clomifene in approximately three quarters of the subjects. This was comparable with studies done in other countries5. In women who responded, nearly 80% did so at a dose of 100mg per day.

Table 1. The association of factors studied with clomifene resistance

<table>
<thead>
<tr>
<th>Factor studied</th>
<th>CC resistant (n=29)</th>
<th>CC responsive (n=99)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age; mean (SD)</td>
<td>28.3 (4.2)</td>
<td>28.3 (5.0)</td>
<td>0.969</td>
</tr>
<tr>
<td>Infertility &gt; 3yrs</td>
<td>13 (44.8)</td>
<td>28 (28.1)</td>
<td>OR 2.06 (95% CI 1.51-9.14)</td>
</tr>
<tr>
<td>BMI &gt; 25 kg/m²</td>
<td>17 (58.6)</td>
<td>52 (52.5)</td>
<td>1.28</td>
</tr>
<tr>
<td>Hirsutism</td>
<td>14 (48.3)</td>
<td>25 (25.2)</td>
<td>2.76</td>
</tr>
<tr>
<td>Mean ovarian volume: cm³</td>
<td>8.46(3.19)</td>
<td>7.57(3.37)</td>
<td>0.208</td>
</tr>
<tr>
<td>Mean AFC</td>
<td>16.0 (7.1)</td>
<td>13.3 (6.1)</td>
<td>0.04</td>
</tr>
<tr>
<td>PCOS</td>
<td>24 (82.8)</td>
<td>61 (61.6)</td>
<td>2.99</td>
</tr>
<tr>
<td>LH:FSH&gt;1</td>
<td>17 (58.6)</td>
<td>31 (31.3)</td>
<td>3.11</td>
</tr>
</tbody>
</table>

Expressed as no (%) unless mentioned. Significant associations are shown in bold.

Imani et al, which achieved ovulation with clomifene in 77% of subjects included11. With an acceptable difference up to 10% of the assumed incidence, a sample size of 107 was calculated using WinPepi computer software, to describe the incidence of a satisfactory response to clomifene in this population. With an estimated drop up rate up to 20% a total of 128 was included in the study.
or less. The incidence of clomifene resistance was 22%.

The factors associated with clomifene resistance in our study population included a longer duration of infertility (> 3 years), presence of hirsutism, PCOS, a higher AFC count and an LH:FSH ratio of >1. Researchers in other countries have also described these. Among these an abnormal LH:FSH ratio showed the strongest correlation where women with such hormone abnormality are three times more likely to be resistant to clomifene. Most features associated with clomifene resistance are clinical and laboratory findings associated with PCOS thus indicating the limitations of its use in this condition. These findings are useful in patient counselling and predicting treatment success in women who present with infertility associated with WHO group II anovulation.

Newer therapeutic agents such as Letrozole, a third generation aromatase inhibitor, has been proposed as an alternative to clomifene in induction of ovulation in recent times. While many use it as a second line agent in clomifene resistance or treatment failure in spite of achieving ovulation, many argue that it should be a potential alternative to clomifene as a first line agent. However, its place in management protocols has not been clearly established. This debate, which has been ongoing for some time, was swayed in favour of Letrozole with recent publications of a well conducted adequately powered study which demonstrated it to be superior to clomifene in women with PCOS. This may partly be due to the limitations of clomifene in women with PCOS as seen in our study. Though the clinical use of Letrozole was cautioned following a small study, which demonstrated a higher rate of congenital anomalies with its use, later studies did not support this hypothesis. Furthermore, as it has a very short half-life (45 hours), it is very unlikely to have adequate amounts of blood levels at the time of conception to cause any teratogenicity. Therefore, its use among women with above factors associated with clomifene resistance should be considered and further research on the use of Letrozole in such women should be undertaken. Early conversion to gonadotropin is also an alternative in such women.

This study had its own limitations. Firstly, we were not able to see the effect of factors such as age and BMI on treatment response to clomifene as the study population was relatively young (mean 28.3 years; 95% CI 27.5-29.1) and with a normal BMI (mean 25.4 kg/m²; 95% CI 24.3-26.4). Both these factors have shown to be associated with Clomifene resistance in previous studies.

ACKNOWLEDGEMENTS

This study was funded by the National Science Foundation (NSF) of Sri Lanka through a research grant (Grant no RG/2007/H5/08).

REFERENCES